Daily Ards Research Analysis
Three studies collectively refine ARDS care and mechanisms: a secondary analysis of a multicenter RCT identifies 8–12 h/day as the optimal awake prone positioning duration to minimize intubation or death; a mechanistic eLife study shows therapeutic hypothermia disrupts the IL-1β–NET pathway to prevent ventilator-induced lung injury; and a porcine model reveals 24-hour prone positioning enhances V/Q matching and oxygenation with minimal extrapulmonary harm but possible renal apoptosis.
Summary
Three studies collectively refine ARDS care and mechanisms: a secondary analysis of a multicenter RCT identifies 8–12 h/day as the optimal awake prone positioning duration to minimize intubation or death; a mechanistic eLife study shows therapeutic hypothermia disrupts the IL-1β–NET pathway to prevent ventilator-induced lung injury; and a porcine model reveals 24-hour prone positioning enhances V/Q matching and oxygenation with minimal extrapulmonary harm but possible renal apoptosis.
Research Themes
- Optimization of prone positioning dosing in acute hypoxemic respiratory failure
- Inflammation–NETs axis targeting to mitigate ventilator-induced lung injury
- Translational physiology of prolonged prone positioning and organ safety
Selected Articles
1. Impact of awake prone positioning duration on intubation or mortality in COVID-19 patients with acute respiratory failure: secondary analysis of a randomized clinical trial.
In a secondary analysis of a multicenter RCT dataset (n=408) in COVID-19 AHRF, longer daily awake prone positioning was linked to lower risk of intubation or death, with benefit concentrated in the first 3 days. A nonlinear association identified 8–12 hours/day as optimal; <8 hours increased risk, whereas >12 hours conferred no added benefit.
Impact: Identifying an optimal APP duration provides an actionable target for care protocols and quality metrics, bridging evidence from RCTs to bedside implementation.
Clinical Implications: Implement APP protocols that aim for 8–12 hours/day, especially during the first 72 hours, and track adherence; extending beyond 12 hours is unlikely to add benefit and may increase burden.
Key Findings
- Longer daily APP duration was associated with reduced risk of intubation or death (HR 0.93 per hour; 95% CI 0.88–0.98).
- The protective association was significant only during the first 3 days after randomization.
- A nonlinear relationship indicated an optimal APP duration of 8–12 h/day; <8 h increased risk (HR 2.44), >12 h offered no additional benefit (HR 1.03).
Methodological Strengths
- Time-dependent Cox modeling with nonlinear assessment in a multicenter trial dataset
- Predefined exposure window (first 7 days) and clinically meaningful composite outcome with 28-day follow-up
Limitations
- Secondary analysis with non-randomized exposure to APP duration introduces potential residual confounding (e.g., tolerance/severity).
- Limited to COVID-19 AHRF; generalizability to non-COVID ARDS remains uncertain.
Future Directions: Pragmatic trials or adaptive protocols prescribing 8–12 h/day APP targets; test applicability in non-COVID ARDS and evaluate patient-centered outcomes and safety.
BACKGROUND: Compared with shorter awake prone positioning (APP), prolonged APP (≥ 12 h daily) reduces the intubation rate in patients with COVID-19-related acute hypoxemic respiratory failure (AHRF). However, the optimal APP duration is uncertain. In this secondary analysis, we aimed to explore whether a longer APP duration is associated with improved outcomes and to identify the optimal duration of APP. METHODS: Data from a multicenter randomized controlled trial involving nonintubated COVID-19 patients with AHRF were analyzed. Daily APP duration over 7 days after randomization was recorded as the primary exposure in present study. The primary outcome was the time from randomization to APP failure, which was defined as a composite of tracheal intubation or mortality within 28 days. A Cox proportional hazards regression model was employed to elucidate the associations, and the daily duration of APP was treated as time dependent. RESULTS: A total of 409 patients were randomized in the original trial, and 408 were enrolled in this analysis. Among these patients, 105 (25.7%) experienced APP failure. A longer daily APP duration was associated with a lower risk of APP failure, with a hazard ratio (HR) of 0.93 (95% confidence interval (CI): 0.88-0.98), and the association was significant only during the first three days after randomization. There was a nonlinear relationship between the daily APP duration and the risk of APP failure (P = 0.015 for nonlinearity). Compared with patients whose APP duration ranged from 8 to 12 h per day, patients with less than 8 h of APP per day had a greater risk of APP failure (HR 2.44, 95% CI 1.21-4.92), whereas extending APP beyond 12 h per day did not improve the outcomes further (HR 1.03, 95% CI 0.51-2.10, P = 0.932). INTERPRETATION: A longer daily APP duration was associated with a reduced risk of APP failure in COVID-19-related AHRF patients, and the optimal APP duration was 8-12 h per day. Clinical trial ClinicalTrials.gov: NCT05677984, Registered January 3, 2023. https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000CST9&selectaction=Edit&uid=U0000YKY&ts=4&cx=-x0muek.
2. Hypothermia protects against ventilator-induced lung injury by limiting IL-1β release and NETs formation.
Using an LPS plus high-volume ventilation mouse model, the study shows IL-1β drives NET formation, worsening lung injury, and that cooling to 32°C reduces IL-1β, prevents NETs, and limits injury. Complementary immune-cell assays support that hypothermia dampens key inflammatory steps, nominating therapeutic hypothermia as a potential lung-protective strategy during mechanical ventilation.
Impact: Identifies an actionable mechanistic axis (IL-1β–NETs) modulated by hypothermia, offering a non-pharmacologic, scalable approach to reduce VILI risk.
Clinical Implications: Supports evaluating targeted therapeutic hypothermia protocols during high-risk ventilation to attenuate inflammation-driven injury, with careful safety assessment.
Key Findings
- In LPS plus high-volume ventilation, IL-1β enhanced NET formation that clogged alveoli and induced acute lung injury.
- Cooling to 32°C significantly reduced lung damage, lowered IL-1β levels, and prevented NET formation.
- Immune-cell assays showed hypothermia slowed key inflammatory steps, supporting a mechanistic link between hypothermia and reduced NETosis.
Methodological Strengths
- Integrated in vivo ARDS/VILI mouse model with mechanistic in vitro immune-cell assays
- Clear causal chain linking IL-1β signaling, NET formation, and hypothermia intervention
Limitations
- Preclinical animal and cell data without human validation; precise timing/temperature windows for clinical use remain undefined.
- Potential off-target effects of hypothermia (e.g., coagulation, infection risk) not addressed.
Future Directions: Phase I/II trials to assess safety, feasibility, and dose (temperature/duration) of targeted hypothermia in patients at risk for VILI; biomarker studies of IL-1β/NETs to guide selection.
Although mechanical ventilation is a critical intervention for acute respiratory distress syndrome (ARDS), it can trigger an IL-1β-associated complication known as ventilator-induced lung injury. In mice, we found that lipopolysaccharide (LPS) and high-volume ventilation, LPS-HVV, lead to hypoxemia with neutrophil extracellular traps (NETs) formation in the alveoli. Furthermore, Patients suffering from acute respiratory distress syndrome, a serious illness that can affect people with existing conditions, usually require ventilators to assist them with breathing. However, ongoing inflammation and changes to their conditions can complicate this breathing support, sometimes causing ventilator-induced lung injury (VILI). VILI can lead to fluid accumulation in the lungs, tissue damage and abnormally low oxygen levels in the blood. The condition has been linked to immune cells, called neutrophils, which release sticky webs as a defense against invading microorganisms. However, together with a mediator of the inflammatory immune response, the cytokine IL-1β, these neutrophil extracellular traps, or NETs, can worsen inflammation and increase damage to the lungs. Scientists have been searching for ways to mitigate this damage, and one promising strategy is therapeutic hypothermia, a controlled method of lowering body temperature. However, it has been unclear if cooling can affect the release of IL-1β and the formation of NETs. To find out more, Nosaka et al. used a mouse model of acute respiratory distress syndrome and VILI. The researchers injected mice with lipopolysaccharide to mimic the clinical setting of ventilated patients under infection-induced septic shock, or saline solution as a control, and exposed them to high ventilation. They then measured blood pressure, blood oxygen levels and immune factors in the lung. This revealed that IL-1β boosts NET formation, which clogged the mice’s lungs and induced acute lung injury. Cooling the mice’s bodies to 32°C significantly reduced lung damage. It also lowered IL-1β levels and prevented the formation of NETs, thus protecting the lungs. Further tests on immune cells showed that hypothermia slowed key steps in inflammation, which reduced harmful immune responses. These results suggest that lowering the body temperature could be a simple and effective way to protect lungs when ventilators are needed, which could be beneficial in the treatment of conditions such as acute respiratory distress syndrome, COVID-19 or other severe lung diseases. Therapeutic hypothermia could become an easy, non-invasive way to protect the lungs of critically ill patients and improve hospital care. However, before this treatment can be widely used, clinical trials in humans are needed to confirm its safety and effectiveness.
3. Pulmonary and Extrapulmonary Effects of Prolonged Prone Positioning in a Porcine Model of Acute Respiratory Distress Syndrome.
In a randomized porcine ARDS model, 24-hour prone positioning improved oxygenation and dorsal V/Q matching and reduced dorsal lung edema without worsening respiratory mechanics or most extrapulmonary markers. A higher renal apoptotic index suggests the need for renal monitoring during prolonged proning.
Impact: Provides translational physiological evidence for prolonged proning benefits and delineates organ safety signals, informing protocol duration and monitoring priorities.
Clinical Implications: Supports prolonged proning to improve oxygenation and V/Q matching while recommending renal monitoring; may guide balancing proning duration with organ safety.
Key Findings
- 24-hour prone positioning significantly improved PaO2/FiO2 and dorsal ventilation, perfusion, and V/Q matching on EIT.
- Dorsal lung wet-to-dry ratio was reduced in the prone group, indicating less edema, without differences in respiratory mechanics or histopathological injury.
- No major extrapulmonary harm was observed except for a higher renal apoptotic index in the prone group.
Methodological Strengths
- Randomized allocation in a large-animal ARDS model with comprehensive physiologic and imaging assessments (EIT).
- Systematic multi-organ evaluation including histopathology, apoptosis, oxidative stress, and biomarkers.
Limitations
- Small sample size (n=9 analyzed) limits precision and detection of rare adverse effects.
- Porcine lavage model may not fully recapitulate human ARDS heterogeneity; 24-hour window only.
Future Directions: Clinical studies to evaluate renal outcomes and biomarkers during prolonged proning; testing varying durations and patient selection criteria.
BACKGROUND: Prone positioning (PP) improves survival in severe acute respiratory distress syndrome (ARDS), but its prolonged effects on pulmonary and extrapulmonary organs remain unclear. This study aimed to investigate the pathophysiological effects of 24-hour PP in a porcine ARDS model. METHODS: Ten female Bama mini swine (49.5 ± 3.7 kg) underwent severe ARDS induction via repeated saline lavage and were randomized to PP (n = 5) or supine position (SP, n = 5). Respiratory parameters, electrical impedance tomography (EIT), haemodynamics, and biochemical serum analysis were performed. After 24 hours, regional lung injury was assessed via histopathology and wet-dry weight (W/D) ratio, and extrapulmonary injury was evaluated by histopathology, apoptosis, oxidative stress, and organ-specific injury biomarkers. RESULTS: Nine swine were analyzed (PP, n = 5; SP, n = 4). PP significantly improved the PaO2/FiO2 ratio. EIT showed sustained improvements in ventilation, perfusion, and ventilation-perfusion matching (V/Q matching), particularly in the dorsal regions. W/D ratio in the dorsal lung was significantly lower in the PP group, with no significant differences in respiratory mechanics or histopathological lung injury. Haemodynamic parameters, intra-abdominal pressure, and serum biochemical analyses showed no significant differences. Extrapulmonary injury analysis revealed no differences, except for a higher apoptotic index in renal tissue in the PP group. CONCLUSIONS: Prolonged PP improved oxygenation by improving ventilation, perfusion, and V/Q matching, while reducing dorsal lung edema, without significantly affecting respiratory mechanics or histopathological lung injury. Additionally, PP showed no significant damage on haemodynamics and extrapulmonary organ function. However, attention should be given to potential renal impairment during prolonged PP administration.